Non-Hodgkin Lymphoma Clinical Trials in Gilbert, Arizona

4 studies are recruiting for non-hodgkin lymphoma in Gilbert, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

    This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Banner MD Anderson Cancer Center, Gilbert, Arizona
    Locations
    11 in total
    Run by
    Miltenyi Biomedicine GmbH

    See if you can join NCT06116110 on ClinicalTrials.gov

  2. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Banner MD Anderson Cancer Center, Gilbert, Arizona
    Locations
    36 in total
    Run by
    Lyell Immunopharma, Inc.

    See if you can join NCT07188558 on ClinicalTrials.gov

  3. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Stage
    Not phased
    Ages
    Any age
    Site
    Banner MD Anderson Cancer Center, Gilbert, Arizona
    Locations
    142 in total
    Run by
    Center for International Blood and Marrow Transplant Research

    See if you can join NCT01351545 on ClinicalTrials.gov

  4. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Banner Health - MD Anderson Cancer Center, Gilbert, Arizona
    Locations
    36 in total
    Run by
    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.